4D Molecular Therapeutics Files for IPO, Applies to List on Nasdaq
September 30 2019 - 7:55PM
Dow Jones News
By Josh Beckerman
4D Molecular Therapeutics Inc., a developer of gene-therapy
products, has filed for an initial public offering.
Viking Global Investors, which led a $90 million Series B
financing round last year, owns a 16% stake. Pfizer Inc. (PFE) owns
11.8%.
4D Molecular, based in Emeryville, Calif., has applied to list
on the Nasdaq Global Market under symbol DDDD. The filing lists a
placeholder figure of $100 million.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
September 30, 2019 19:40 ET (23:40 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2023 to Sep 2024